-
Featured Authors
-
Archives
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: health
New Treatments Needed for Obesity
![OW2014_jumbotron_R02[1]](http://www.biotech-now.org/wp-content/uploads/2014/10/OW2014_jumbotron_R021.jpg)
ObesityWeek 2014, Nov. 2-7, in Boston Offers Opportunities to Learn & Connect Coauthored by The Obesity Society Public Affairs Chair & Co-Chair Adam Tsai, MD, Internal Medicine & Weight Management Physician, Kaiser Permanente Colorado Amanda Staiano, PhD, Assistant Professor, Pennington Biomedical Research Center Obesity is one of the most pervasive, chronic diseases in need of new strategies for medical treatment and prevention. As a leading cause of mortality, morbidity, disability, healthcare utilization and healthcare costs, Read More >
Patient and Venture Philanthropy Groups Presenting at 2014 BIO Investor Forum
BIO’s alliance development team works to foster collaboration between the biotech industry and nonprofit disease foundations. In recent years, many nonprofit foundations have become more engaged in the drug development process – whether they have created clinical trial recruitment tools, established a disease registry, or funded emerging biotech companies. Recognizing the value of these initiatives to expedite research and drug development, BIO provides opportunities for venture philanthropies and patient organizations to connect with BIO members Read More >
Events
Leave a comment
Email This Post
Tags: 2014 BIO Investor Forum, BIO EVENT, BIO Investor Forum, Blood cancer research, diabetes, health, Juvenile Diabetes Research Foundation, Leukemia & Lymphoma Society, Michael J. Fox Foundationfor Parkinson’s Research, Parkinson's disease, patient, Rare Cancer Research Foundation
Tags: 2014 BIO Investor Forum, BIO EVENT, BIO Investor Forum, Blood cancer research, diabetes, health, Juvenile Diabetes Research Foundation, Leukemia & Lymphoma Society, Michael J. Fox Foundationfor Parkinson’s Research, Parkinson's disease, patient, Rare Cancer Research Foundation
The Hill: In War on Cancer, Patients at Risk of Becoming Commoditized
Ted Okon, executive director of the Community Oncology Alliance, highlights the significant progress the medical community has made in the war on cancer but stresses the importance of access to care to improve and lengthen patients’ lives. “More Americans with cancer face longer life expectancies as a result of increased awareness among at-risk populations, better preventative care, early screenings, and new therapies,” writes Okon. “However, despite significant progress in the war on cancer, unnecessary access Read More >
Mito What???
Mitochondrial Disease: The Most Common Disease You’ve Probably Never Heard of… About 20 years ago, mitochondrial disease was virtually unheard of. Just 10 years ago, it was considered rare. Today, according to NORD, a disease is considered rare when less than 200,000 people are affected. Mitochondrial disease is not a single disease, but rather an entire umbrella of rare diseases. For example, Alpers disease and Barth syndrome are very different and rare forms of mitochondrial Read More >
Health
Leave a comment
Email This Post
Tags: advocacy, ALS, alzheimers, awareness, cancer, diabetes, FDA, FDASIA, genetic, health, Health Care, healthcare, lou gehrig's disease, lupus, mitochondria, mitochondrial disease, mitochondrial dysfunction, MS, Multiple sclerosis, mutation, NORD, ODTC, Orphan Drug Tax Credit, orphan drugs, Parkinson's, patient, patient advocacy, patient advocates, Patient community, patients, rare disease, Rare Disease Drug Development, rare diseases, rheumatoid arthritis
Tags: advocacy, ALS, alzheimers, awareness, cancer, diabetes, FDA, FDASIA, genetic, health, Health Care, healthcare, lou gehrig's disease, lupus, mitochondria, mitochondrial disease, mitochondrial dysfunction, MS, Multiple sclerosis, mutation, NORD, ODTC, Orphan Drug Tax Credit, orphan drugs, Parkinson's, patient, patient advocacy, patient advocates, Patient community, patients, rare disease, Rare Disease Drug Development, rare diseases, rheumatoid arthritis
Playing Detective With Checkpoint Therapies
Three words are on the lips of everyone following new developments in cancer therapies: checkpoint inhibitor drugs. Simply put, investigators believe they have figured out a way to dismantle the mechanism used by cancer cells to stay hidden from T-cells, a type of specialized immune cell. CTLA-4 is a protein on the surface of T-cells that acts as an “off” switch for the sleuthing T-cells. It signals them to remain in a resting state, kind of like Read More >
